Skip to main content
SpringerLink
Log in

Systemic and Regional Hemodynamic Effects of Gallopamil in Patients with Essential Hypertension

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

Systemic and regional hemodynamics were assessed in 10 patients with uncomplicated mild to moderate essential hypertension before and during gallopamil therapy. Cardiac output was measured in triplicate with indocyanine dye. Plasma volume and renal blood flow were measured radioisotopically. Immediately following the initial dose of a slow-release (SR) formulation of gallopamil, a significant fall in arterial pressure associated with a decreased total peripheral resistance and a reflex increase in heart rate and cardiac output were seen. Then, after 8–12 weeks of treatment, arterial pressure and total peripheral resistance remained reduced, but heart rate and cardiac output returned to pretreatment levels. Gallopamil also produced significant reductions in renal and splanchnic vascular resistance. Plasma volume and total blood volume did not change. Thus, gallopamil reduced arterial pressure and vascular resistances without fluid retention or prolonged reflexive changes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bursztyn M, Grossman E, Rosenthal T. Long-acting nifedipine in moderate and severe hypertensive patients with serious concomitant diseases. Am Heart J 1985;110:96-101.

    Google Scholar 

  2. Amodeo C, Kobrin I, Ventura HO, Messerli FH, Frohlich ED. Immediate and short-term hemodynamic effects of diltiazem in patients with hypertension. Circulation 1986;73:108-113.

    Google Scholar 

  3. Lund Johansen P, Omvik P. Haemodynamic effects of calcium antagonists at rest and during exercise in essential hypertension: A comparison between verapamil, diltiazem, tiapamil, nefedipine, nisoldipine. In: Aoki K, ed. Essential Hypertension 2. Tokyo: Springer-Verlag, 1989:339-351.

    Google Scholar 

  4. Mueller FB, Bolli P, Erne P, Kiowski W, Bühler FR. Calcium antagonism--a new concept for treating essential hypertension. Am J Cardiol 1986;57:50D-3D.

    Google Scholar 

  5. Kaplan NM. Calcium entry blockers in the treatment of hypertension. Current status and future prospects. JAMA 1989;262:817-823.

    Google Scholar 

  6. Cummings DM, Amadio P Jr, Nelson L, Fitzgerald JM. The role of calcium channel blockers in the treatment of essential hypertension. Arch Intern Med 1991;151:250-259.

    Google Scholar 

  7. Messerli FH, Aepfelbacher FC. Cardiac effects of calcium antagonists in hypertension. In: Messerli FH, ed. Cardiovascular Drug Therapy, 2nd ed. Philadelphia: W. B. Saunders, 1996;908-915.

    Google Scholar 

  8. Joint National Committee on the Detection, Evaluation, and Treatment of Blood Pressure. The 1992 Report of the Joint National Committee on the Detection, Evaluation, and Treatment of Blood Pressure (JNC-V). Arch Intern Med 1993;153:154-183.

    Google Scholar 

  9. Zanchetti A, Chalmers J, Arakawa K, et al. Guidelines Subcommittee. 1993 Guidelines for the management of mild hypertension: Memorandum from a World Health Organization/International Society of Hypertension meeting. J Hypertens 1993;11:905-918.

    Google Scholar 

  10. Brogden RN, Benfield P. Gallopamil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in ischaemic heart disease. Drugs 1994;47:93-115.

    Google Scholar 

  11. Messerli FH, de Carvalho JGR, Christie B, Frohlich ED. Systemic and regional hemodynamics in low, normal and high cardiac output borderline hypertension. Circulation 1978;58:441-448.

    Google Scholar 

  12. Ulrych M, Frohlich ED, Tarazi RC, Dustan HP, Page IH. Cardiac output and distribution of blood volume in central and peripheral circulations in hypertensive and normotensive man. Br Heart J 1969;31:570-574.

    Google Scholar 

  13. Meier P, Zierler KL. On theory of indicator-dilution method for measurement of blood flow and volume. J Appl Physiol 1954;6:731-744.

    Google Scholar 

  14. Messerli FH, Nowaczynski W, Honda M, et al. Effects of angiotensin II on steroid metabolism and hepatic blood flow in man. Circ Res 1977;40:204-207.

    Google Scholar 

  15. Sealey JE, Laragh JH, Gerten-Banes J, Aceto RM. The measurement of plasma renin activity in man. In: Laragh JH, ed. Hypertension Manual. Mechanisms, Methods, Management. New York: Yorke Medical Books, 1974:621-640.

    Google Scholar 

  16. Peuler JD, Johnson CA. Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine, and dopamine. Life Sci 1977;21:625-636.

    Google Scholar 

  17. Tan SY, North Q, Mulrow PJ. Direct non-chromatographic radioimmunoassay of aldosterone: Validation of a commercially available kit and observations on age-related changes in concentration in plasma. Clin Chem 1978;24:1531-1533.

    Google Scholar 

  18. Schmieder RE, Messerli FH, Garavaglia GE, Nunez BD. Cardiovascular effects of verapamil in patients with essential hypertension. Circulation 1987;75:1030-1036.

    Google Scholar 

  19. Grossman E, Oren S, Garavaglia GE, Messerli FH, Frohlich ED. Systemic and regional hemodynamic and humoral effects of nitrendipine in essential hypertension. Circulation 1988;78:1394-1400.

    Google Scholar 

  20. Kusaka M, Atarashi K, Matsumoto K, et al. Plasma renin activity and nor-epinephrine as predictors for antihypertensive effects of nifedipine and captopril. Am J Hypertens 1991;4:735-739.

    Google Scholar 

  21. Grossman E, Messerli FH, Oren S, Nunez B, Garavaglia GE. Cardiovascular effects of isradipine in essential hypertension. Am J Cardiol 1991;68:65-70.

    Google Scholar 

  22. Burges R, Moisey D. Unique pharmacologic properties of amlodipine. Am J Cardiol 1994;73:2A-9A.

    Google Scholar 

  23. Dei Cas L, Metra M, Ferrari R, Visioli O. Acute and chronic effects of the dihydropyridine calcium antagonist nisoldipine on the resting and exercise hemodynamics, neurohumoral parameters, and functional capacity of patients with chronic heart failure. Cardiovasc Drugs Ther 1993;7:103-110.

    Google Scholar 

  24. Leenen FH, Holliwell DL. Antihypertensive effect of felodipine associated with persistent sympathetic activation and minimal regression of left ventricular hypertrophy. Am J Cardiol 1992;69:639-645.

    Google Scholar 

  25. Iimura O, Shimamoto K. Efficacy and mode of action of manidipline: A new calcium antagonist. Am Heart J 1993;125:635-641.

    Google Scholar 

  26. Leonetti G. The effects of calcium antagonists on electrolytes and water balance in hypertensive patients. J Cardiovasc Pharmacol 1994;24:S25-29.

    Google Scholar 

  27. Epstein M. Calcium antagonists and the kidney. J Cardiovasc Pharmacol 1994;24:S18-24.

    Google Scholar 

  28. Bruun NE, Ibsen H, Nielsen F, Nielsen MD, Moelbak AG, Hartling OJ. Lack of effect of nifedipine on counterregulatory mechanisms in essential hypertension. Hypertension 1986;8:655-661.

    Google Scholar 

  29. Lindqvist M, Kahan T, Melcher A, Hjemdahl P. Acute and chronic calcium antagonist treatment elevates sympathetic activity in primary hypertension. Hypertension 1994;24:287-296.

    Google Scholar 

  30. Ruzicka M, Leenen FHH. Relevance of intermittent increases in sympathetic activity for adverse outcome on short-acting calcium antagonists. In Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management. New York: Raven Press, 1995:2815-2825.

    Google Scholar 

  31. Laragh JH, Held C, Messerli F, Pepine C, Sleight P. Calcium antagonists and cardiovascular prognosis: A homogeneous group? Am J Hypertens 1996;9:99-109.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Poliklinik, Director Prof. Dr. J. Scholze, Universitäts-Klinikum Charité, Berlin, Germany

    Reinhard G. Ketelhut

  2. Department of Internal Medicine, Section on Hypertension, Ochsner Clinic and Alton Ochsner Medical Foundation, New Orleans, Louisiana, USA

    Franz H. Messerli, Christoph Losem, Edward D. Frohlich & Leszek Michalewicz

Authors
  1. Reinhard G. Ketelhut
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Franz H. Messerli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christoph Losem
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Edward D. Frohlich
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Leszek Michalewicz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ketelhut, R.G., Messerli, F.H., Losem, C. et al. Systemic and Regional Hemodynamic Effects of Gallopamil in Patients with Essential Hypertension. Cardiovasc Drugs Ther 11, 39–42 (1997). https://doi.org/10.1023/A:1007743705737

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1007743705737

Search

Navigation